pgl manufacturing contract with prr

Progen Subsidiary Secures New Manufacturing Contracts with Prima BioMed Ltd and Phosphagenics Ltd

Brisbane, Australia, 20 July 2011. Progen Pharmaceuticals Ltd (ASX:PGL, OTC: PGLA) announced today that the company?s biopharmaceuticals manufacturing subsidiary PharmaSynth Pty Ltd, had secured new contracts with Australian biotech companies, Prima BioMed Limited and Phosphagenics Limited.
PharmaSynth has been contracted by Prima BioMed to manufacture mannosylated fusion protein (M-FP). The M-FP will be used as a key starting material in the production of CVac?. Prima BioMed has a forthcoming pivotal clinical trial (CANVAS) to use CVac?, a ?cellular therapy? or ?cancer vaccine?, as a maintenance treatment for patients with Epithelial Ovarian Cancer (EOC) in complete remission. PharmaSynth have previously manufactured M-FP for
Prima BioMed.

PharmaSynth has also been contracted to manufacture TPM? for Phosphagenics. The TPM? technology which comprises vitamin E phosphates has been shown to enhance dermal,
transdermal and oral absorption of compounds and Phosphagenics is using the technology to develop therapeutics, nutraceuticals and personal care products. Phosphagenics is a new client for PharmaSynth.

Progen CEO, Sue MacLeman, said that whilst these individual contracts are not material to Progen?s overall result, PharmaSynth?s new contract with Prima BioMed and the addition of Phosphagenics to its growing list of strategic relationships with innovative Australian biotechnology clients is an important achievement for the growth of PharmaSynth.

PharmaSynth CEO, Les Tillack, said ?These projects fit well with our core areas of expertise in recombinant protein manufacture and chemical synthesis.?

ENDS



good luck